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Objective: To review the reimbursement recommendations issued by selected European 
health technology assessment agencies for orphan drugs and the reimbursement status 
of these drugs; to assess the relationship between the type of recommendation and 
reimbursement status.
Methods: The list of orphan drugs to be included in the analysis was obtained from 
the European Medicines Agency and Orphanet. Seven European states were included 
in the analysis: Belgium, England, France, Germany, Poland, Scotland, and Spain. 
For all identified orphan drugs, relevant data on the reimbursement status and type of 
recommendation were collected for each country. The relationship between the type 
of recommendation and reimbursement status was evaluated separately for each 
considered country, using Cohen’s kappa coefficient for the measurement of agreement; 
sub-analyses for oncology and metabolic drugs were performed.
Results: Most reimbursement recommendations for orphan drugs were positive (71%), 
while approximately 17% were negative and almost 13% were conditional. The highest 
percentage of positive reimbursement recommendations was observed in Spain (97%) and 
France (95%) and the highest percentage of negative reimbursement recommendations 
was revealed for Poland (49%). On average, 65% of the 163 analyzed orphan drugs 
were reimbursed from public funds. The highest number of reimbursed orphan drugs 
was observed in Germany (n = 148), while the lowest, in Poland (n = 41). Considering all 
analyzed drugs, the highest agreement between recommendations and reimbursement 
status was observed for Spain (value of 1), and the lowest, for Germany (κ = -0.03).
Conclusions: On average, more than 60% of identified orphan drugs were reimbursed 
from public funds in the included countries, and the majority of reimbursement 
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BACKGROUND
From the point of view of epidemiology, diseases may be divided 
into common, rare, and ultra-rare. First and foremost, there 
is no uniform criterion for defining rare diseases, applicable 
across countries.
The criterion used in the European Union (EU) assumes that 
a rare disease affects not more than 5 out of every 10,000 people, 
which corresponds to a population of approximately 253,000 EU 
residents (https://www.ema.europa.eu/en/news/development-
medicines-rare-diseases). In line with the definition of the World 
Health Organization, a rare disease is a disease which affects, 
as a maximum, 65 out of 100,000 people, whereas the Swedish 
National Board of Health and Welfare defines a rare disease as 
a disease which affects not more than 10 out of 100,000 people 
in a population. In the United States (US), the Orphan Drug Act 
(1983) features a provision that a rare disease affects fewer than 
200,000 residents in the US (i.e., not more than approx. 7 cases 
per 10,000 patients) (Łanda et al., 2009). In Australia and Japan, 
a rare disease is defined as affecting 11 and 40 people out of 
100,000 people, respectively (Denis et al., 2009). Similarly, there 
are no commonly adopted international or European definitions 
for ultra-rare diseases. In England, this concept entails a 
disease with a prevalence of 1 case per 50,000 people (Łanda 
et al., 2009), while in Poland, an ultra-rare disease is a disease 
which affects not more than 750 people in the population 
(Zarządzenie Nr 17/2007 Prezesa Narodowego Funduszu 
Zdrowia z dnia 10 kwietnia 2007 r. w sprawie zasad wdrażania 
terapeutycznych programów zdrowotnych finansowanych przez 
Narodowy Fundusz Zdrowia, 2007). The value mentioned above 
corresponds to the definition of an ultra-rare disease adopted in 
England, i.e., 1:50,000 people.
An orphan drug is a medicinal product that is developed 
to treat, diagnose, or prevent a specific rare disease (European 
Medicines Agency, 2018). In recent decades, more and more 
medicines have been approved for rare indications. Additionally, 
special programmes have been developed to better diagnose, 
prevent, and treat those conditions (World Health Organization).
However, many rare diseases stay without treatment. Medicines 
for which the targeted population is small are commercially 
unattractive for the pharmaceutical industry. Many orphan 
drugs would not be developed and authorized without additional 
incentives (Franco, 2013). The EU regulatory framework allows 
marketing authorization holders for orphan drugs to: 1) obtain 
scientific advice on clinical trial protocols at a reduced charge, 
2) gain access to the European Medicines Agency centralized 
licensing procedure, 3) get reduction of registration costs, and 
4) benefit from 10 years of market exclusivity after registration 
(European Medicines Agency, 2018).
Clinical development and market authorization of orphan 
drugs is not enough. Orphan drugs must also be reimbursed 
from public funds to be accessible to patients, particularly as 
their prices are usually significantly higher than those of drugs 
for common diseases. Reimbursement decisions are increasingly 
based on health technology assessment (HTA), usually entailing 
economic evaluation. HTA agencies issued reimbursement 
recommendations which may be positive, negative, or conditional 
(positive after fulfilling additional conditions). Based on the 
HTA agency recommendations, decision makers, responsible for 
drug reimbursement, produce a final decision on reimbursement 
which may be positive or negative. Positive reimbursement 
recommendation does not guarantee reimbursement, and 
similarly negative reimbursement recommendation does not 
always mean a lack of reimbursement. Economic evaluations 
of orphan drugs are particularly difficult as available clinical 
data are limited and there are usually no relevant comparators. 
Resource use and costs of treatment are also challenging to 
calculate because very few clinical centers are specialized in 
diagnosing and treating rare diseases—collected values may be 
non-representative, and for many countries even not available. 
Due to their high prices, orphan drugs usually have a very high 
incremental cost-effectiveness ratio (ICER), which typically 
surpasses willingness-to-pay thresholds set in different systems 
and may lead to negative reimbursement recommendations 
issued by HTA agencies and an exclusion from reimbursement. 
Some countries set different, higher thresholds for orphan 
drugs than for medicines used in common conditions. The 
example of such country is the Netherlands, where no drugs 
have been excluded from coverage because of their unfavorable 
cost-effectiveness (Carrera and IJzerman, 2016). Governments 
may decide to reimburse orphan drugs despite a negative 
recommendation, if they constitute the only therapeutic option 
for a selected group of patients (Kawalec et al., 2018).
To provide an overview of the availability of orphan drug 
funding in statutory health systems in Europe, this study aimed 
to review reimbursement recommendations issued by European 
HTA agencies for orphan drugs and the reimbursement status 
of these drugs. This study will also answer the question if 
reimbursement recommendation of considered HTA agency 
for orphan drug corresponds with reimbursement status. 
Additionally, the subgroups of drugs registered in oncological 
and metabolic indications were analyzed separately.
METHODS
The full list of orphan drugs to be included in the analysis was 
obtained from the website of the European Medicines Agency 
recommendations were found to be positive. The agreement between reimbursement 
recommendations and reimbursement status differed between the countries, but overall, 
it did not show any patterns, as it ranged from -0.03 to 1 (κ coefficient).
Keywords: health technology assessment, drug policy, rare disease, reimbursement, orphan
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(2018) and Orphanet (2018). All orphan drugs registered till 
end of July 2018 by the European Medicines Agency (EMA) 
were included. The following European states, for which both 
reimbursement and recommendation data were available, were 
included in the analysis: England, France, Germany, Poland, 
Scotland, and Spain. Additionally, Belgium was included, but 
only the reimbursement status was available for this country. The 
countries were selected to represent a mixture of health system 
financing modalities and expected availability of reimbursed 
orphan drugs. Information on reimbursement status and type 
of recommendation was collected by experts in each included 
country using publicly available information (Supplementary 
Table 1). Schematic figure on methodology was presented in 
Supplementary Figure 1.
Drugs with multiple rare indications were treated as 
one observation (all indications of the drug treated as one). 
Reimbursement recommendations were coded as follows: 
negative—reimbursement from the public fund is not 
recommended, positive—reimbursement from public fund is 
recommended, or conditional—reimbursement is recommended 
but only if additional conditions are met. This coding was not 
directly applicable for Germany, as new medicines are generally 
automatically reimbursable upon marketing authorization; 
this is picked up further in the Discussion section. Only the 
reimbursement status was assessed, but no information on drug 
availability in each country was collected. The data on the type of 
reimbursement recommendations and reimbursement status were 
summarized with counts and percentages. As more than 30% of the 
orphan drugs included in the analysis were registered in oncological 
indications, and about 20% were registered in metabolic indications, 
those subgroups of drugs were also analyzed separately.
As reimbursement policy and HTA agency guidelines for 
orphan drugs differ among European countries, the relationship 
between the type of recommendation and reimbursement status 
was assessed separately for each country. The agreement between 
recommendations and reimbursement status for each country 
separately as well as between countries (for both recommendations 
and reimbursement status) was assessed using Cohen’s kappa 
coefficient of agreement (κ) for the measurement of agreement. 
The κ coefficient can range from -1 to 1, with values lower than 0 
denoting no agreement, 0 representing the amount of agreement 
by random chance, and 1 denoting perfect agreement. The values 
between 0.01 and 0.20 denote slight agreement, between 0.21 
and 0.40—fair agreement, between 0.41 and 0.60—moderate 
agreement, between 0.61 and 0.80—substantial agreement, 
and between 0.81 and 0.99—almost perfect agreement (Cohen, 
1960). All κ coefficients were supported with 95% confidence 
intervals and rounded to two decimal places.
RESULTS
Overall 163 orphan drugs were identified in EMA and Orphanet 
databases, including 54 drugs with oncological indication and 33 
drugs with metabolic indication; the list was valid for July 2018 
(Supplementary Table 2).
Reimbursement Recommendations for 
Orphan Drugs
We identified 526 reimbursement recommendations, which 
were issued for the analyzed orphan drugs in all countries. 
The highest number of recommendations was identified 
in France (n  = 131), Scotland (n = 108), and Spain (n = 
103). Considering all states, the majority of reimbursement 
recommendations for orphan drugs were positive (71%), 
while 17% were negative and almost 13% were conditional. 
The highest percentage of positive reimbursement 
recommendations was observed in Spain (97%) and France 
(95%). In England there was a similar percentage of positive 
and conditional reimbursement recommendations—42% 
and 47%, respectively. The highest percentage of negative 
reimbursement recommendations was observed in Poland 
(49%) and Scotland (32%). In France, the HTA agencies issued 
no conditional reimbursement recommendations for orphan 
drugs (Figure 1).
About 41% (216 out of 526) of reimbursement recommendations 
were issued for orphan drugs used for oncologic indications. The 
highest percentage of recommendations for oncologic drugs 
among all recommendations for orphan drugs was observed in 
England (63.6%), Poland (44.1%), and Scotland (40.7%), while 
the lowest, in France (35.1%). Considering all analyzed countries, 
the majority of reimbursement recommendations for oncologic 
orphan drugs were positive (69%), while 16% were negative 
and 15% were conditional. The highest percentage of positive 
reimbursement recommendations for oncologic orphan drugs 
was observed in France (96%) and Spain (95%), while the lowest, 
in Poland (40%) (Table 1).
About 17% (89 out of 526) of reimbursement 
recommendations were issued for orphan drugs used for 
metabolic indications. The percentage of recommendations for 
metabolic drugs among all recommendations for orphan drugs 
was similar between the countries. Considering all analyzed 
countries, the majority of reimbursement recommendations 
for metabolic orphan drugs were positive (75%), while 20% 
FIGURE 1 | Percentage of positive, negative, and conditional reimbursement 
recommendations for orphan drugs (all) in analyzed countries
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were negative and 4% were conditional. The highest percentage 
of positive reimbursement recommendations for metabolic 
orphan drugs was observed in Spain, Germany (100%; see 
caveat on the German system in the Discussion section, 
below), and France (96%), while the lowest, in Scotland (31%) 
and Poland (33%) (Table 1).
Reimbursement Status for Orphan Drugs
The reimbursement status was assessed for 163 orphan drugs. 
On average, 65% of analyzed orphan drugs were reimbursed 
from public funds. The highest number of reimbursed orphan 
drugs was observed in Germany (n = 148, 90.8%), England 
(n = 115, 70.6%), Scotland (n = 113, 69.3%), and France 
(n = 112, 68.7%), while the lowest, in Poland (n = 41, 25.2%) 
(Figure 2). Out of the 163 orphan drugs, 54 (33%) were 
used for oncologic indications. On average, 69% of analyzed 
oncologic orphan drugs were reimbursed from public funds, 
with the highest percentage observed in Germany (89%), 
France (80%), England and Scotland (72%), while the lowest, 
in Poland (31%). More than 20% of the analyzed orphan 
drugs were used for metabolic indications. On average, 
64% of analyzed metabolic orphan drugs were reimbursed 
from public funds, with the highest percentage observed in 
Germany (97%), England and Scotland (82%), while the lowest 
in Poland (21%) (Table 2).
Agreement in Reimbursement Status 
Between Countries
Agreement in reimbursement status was assessed among all 
analyzed countries. The highest κ coefficient of agreement for 
all analyzed drugs was 0.91, observed between England and 
Scotland, and the lowest was 0.07, observed between Poland 
and Germany (Table 3; see caveat on the German system in the 
Discussion section). Considering only oncologic orphan drugs, 
the highest agreement (κ = 0.82) was observed between England 
and Scotland. The lowest agreement (κ = 0.11) was observed 
between England and Spain, Scotland and Poland, as well as 
Poland and Germany (Table 4). For metabolic drugs, the highest 
agreement (κ = 1) was observed between England and Scotland, 
and the lowest (-0.07), between Spain and both England and 
Scotland (Table 5).
Agreement in Recommendations  
Between Countries
Agreement in recommendations was also assessed. The highest 
κ coefficient of agreement for all analyzed drugs was 0.57, 
observed between England and Scotland, and the lowest was 
–0.15, observed between Scotland and Germany (Table  6). 
Considering only oncologic orphan drugs, the highest 
agreement (κ = 0.72) was observed between England and 
Scotland, and the lowest (κ = -0.13), between Scotland and 
Germany (Table 7). The highest agreement for metabolic drugs 
was between England and Scotland as well as Scotland and 
Poland (κ = 0.55). Small number of drugs precluded us from 
the calculation of the agreement between other combinations 
of countries (Table 8).
TABLE 1 | Recommendation for oncologic and metabolic drugs.
Drugs Recommendation England Scotland France Spain Poland Germany All
Oncologic Negative 3 (8.6%) 11 (25.0%) 2 (4.3%) 1 (2.6%) 15 (50.0%) 2 (8.7%) 34 (15.7%)
Positive 17 (48.6%) 22 (50.0%) 44 (95.7%) 36 (94.7%) 12 (40.0%) 19 (82.6%) 150 (69.4%)
Conditional 15 (42.9%) 11 (25.0%) 0 (0%) 1 (2.6%) 3 (10.0%) 2 (8.7%) 32 (14.8%)
Metabolic Negative 2 (25.0%) 9 (56.3%) 1 (4.0%) 0 (0%) 6 (66.7%) 0 (0%) 18 (20.2%)
Positive 4 (50.0%) 5 (31.3%) 24 (96.0%) 18 (100%) 3 (33.3%) 13 (100%) 67 (75.3%)
Conditional 2 (25.0%) 2 (12.5%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 4 (4.5%)
FIGURE 2 | Percentage of reimbursed orphan drugs (all) in analyzed 
countries.
TABLE 2 | Reimbursement status for oncologic and metabolic drugs.
Drugs Reimbursement 
status
England Scotland France Spain Poland Germany All
Oncologic Not Reimbursed 15 (27.8%) 15 (27.8%) 11 (20.4%) 17 (31.5%) 37 (68.5%) 6 (11.1%) (31.2%)
Reimbursed 39 (72.2%) 39 (72.2%) 43 (79.6%) 37 (68.5%) 17 (31.5%) 48 (88.9%) (68.8%)
Metabolic Not Reimbursed 6 (18.2%) 6 (18.2%) 12 (36.4%) 14 (42.4%) 26 (78.8%) 1 (3.0%) (32.8%)
Reimbursed 27 (81.8%) 27 (81.8%) 21 (63.6%) 19 (57.6%) 7 (21.2%) 32 (97.0%) (67.2%)
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TABLE 3 | Agreement in reimbursement status between countries for all analyzed drugs.
Scotland France Spain Poland Germany
England 0.91 (0.84–0.98) 0.38 (0.22–0.53) 0.17 (0.02–0.33) 0.18 (0.10–0.27) 0.17 (0.03–0.31)
Scotland 0.33 (0.17–0.48) 0.21 (0.05–0.36) 0.18 (0.09–0.27) 0.16 (0.02–0.30)
France 0.52 (0.39–0.66) 0.22 (0.13–0.31) 0.29 (0.15–0.44)
Spain 0.33 (0.23–0.42) 0.23 (0.11–0.36)
Poland 0.07 (0.03–0.10)
TABLE 4 | Agreement in reimbursement status between countries for oncologic drugs.
Scotland France Spain Poland Germany
England 0.82 (0.64–0.99) 0.40 (0.12–0.67) 0.11 (-0.16 to 0.39) 0.17 (0.00–0.35) 0.26 (-0.01 to 0.54)
Scotland 0.30 (0.01–0.58) 0.20 (-0.07 to 0.48) 0.11 (-0.07 to 0.29) 0.26 (-0.01 to 0.54)
France 0.43 (0.17–0.69) 0.21 (0.08–0.34) 0.52 (0.22–0.82)
Spain 0.35 (0.18–0.52) 0.32 (0.07–0.58)
Poland 0.11 (0.02–0.20)
TABLE 5 | Agreement in reimbursement status between countries for metabolic drugs.
Scotland France Spain Poland Germany
England 1.00 (1.00–1.00) -0.03 (-0.33 to 0.28) -0.07 (-0.35 to 0.21) 0.02 (-0.12 to 0.17) -0.05 (-0.15 to 0.04)
Scotland -0.03 (-0.33 to 0.28) -0.07 (-0.35 to 0.21) 0.02 (-0.12 to 0.17) -0.05 (-0.15 to 0.04)
France 0.62 (0.35–0.89) 0.27 (0.07–0.46) 0.10 (-0.09 to 0.30)
Spain 0.33 (0.11–0.56) 0.08 (-0.07 to 0.23)
Poland 0.02 (-0.02 to 0.05)
TABLE 6 | Agreement in recommendations between countries for all analyzed drugs.
Scotland France Spain Poland Germany
England 0.57 (0.24–0.89) -0.06 (-0.11 to -0.00) -0.04 (-0.10 to 0.02) 0.11 (-0.04 to 0.27) -0.08 (-0.16 to -0.00)
Scotland -0.06 (-0.12 to 0.00) -0.02 (-0.07 to 0.02) 0.30 (0.09–0.50) -0.15 (-0.26 to -0.04)
France -0.03 (-0.05 to -0.00) 0.06 (-0.02 to 0.15) -0.08 (-0.14 to -0.02)
Spain 0.08 (-0.03 to 0.19) -0.08 (-0.16 to -0.00)
Poland 0.08 (-0.12 to 0.28)
TABLE 7 | Agreement in recommendations between countries for oncologic drugs.
Scotland France Spain Poland Germany
England 0.72 (0.35–1.00) -0.07 (-0.13 to -0.00) -0.06 (-0.14 to 0.03) 0.12 (-0.04 to 0.29) -0.07 (-0.16 to 0.03)
Scotland -0.09 (-0.20 to 0.02) -0.05 (-0.15 to 0.04) 0.19 (-0.01 to 0.39) -0.13 (-0.26 to 0.00)
France -0.04 (-0.09 to 0.02) 0.07 (-0.06 to 0.19) -0.07 (-0.16 to 0.03)
Spain 0.06 (-0.06 to 0.19) -0.09 (-0.21 to 0.04)
Poland -0.05 (-0.33 to 0.23)
TABLE 8 | Agreement in recommendations between countries for metabolic drugs.
Scotland France Spain Poland Germany
England 0.55 (-0.16 to 1.00) NA NA NA NA
Scotland NA NA 0.55 (-0.16 to 1.00) NA
France NA NA NA
Spain NA NA
Poland NA
NA not available; impossible to assess due to small number of cases.
Frontiers in Pharmacology | www.frontiersin.org November 2019 | Volume 10 | Article 1279
Reimbursement and Recommendations for ODs in European CountriesStawowczyk et al.
6
Agreement Between Recommendations and 
Reimbursement Status Within Countries
Considering all analyzed drugs, the highest κ coefficient of agreement 
between recommendations and reimbursement status was observed 
for Spain (κ = 1) and the lowest, for Germany (κ = -0.03; please 
refer to comment in Discussion) (Figure 3). For the subgroup of 
oncologic drugs, the corresponding κ values were 1 for Spain and 0 
for Germany (Figure 4). For metabolic drugs, the corresponding κ 
values were 0.31 for Poland and -0.3 for England (Figure 5).
DISCUSSION
This study analyzed the type of reimbursement recommendations 
issued for orphan drugs in selected European countries, together 
with the reimbursement status. Most Western European countries 
were included in the analysis, but only one from Central Eastern 
Europe (CEE; Poland). The reason for that was because data on 
reimbursement status and reimbursement recommendations were 
not available in other CEE countries; Poland was the only CEE state 
with relevant data on drug reimbursement widely available online.
No detailed information on the reimbursement 
recommendations for individual orphan drugs was available in 
Belgium. Overall, in 2016, the Drug Reimbursement Committee 
issued 27% of positive and 27% of negative recommendations. 
The Committee was not able to issue any recommendations in 
the case of 9% of the assessed orphan drugs, and it advised to 
negotiate the managed entry agreement in 37% of cases. Taking 
those recommendations into account, the Minister issued 
positive decisions on the reimbursement of 73% of orphan drugs, 
and negative in 27%.
In Germany, new medicines are reimbursable upon entering in 
the market; manufacturers can set their price freely for the first year 
of circulation. Early benefit assessment of new active substances 
by the Federal Joint Committee (Gemeinsamer Bundesausschuss, 
G-BA) was introduced by the Pharmaceutical Market Restructuring 
Act (Arzneimittelmarktneuordnungsgesetz, AMNOG), which 
came into force on 1st January 2011. Drugs with new active 
substances undergo a benefit assessment based on an evidence 
dossier submitted by the manufacturer. The G-BA classifies the 
magnitude of the new drug’s added benefit compared to current 
best practice. This classification is the basis for the negotiation of 
the drug’s reimbursement price between the German Association 
of Statutory Health Insurance Funds and the manufacturer, 
which applies after the first year of circulation. In most cases, the 
reimbursement status remains unaffected. To allow for the special 
characteristics of orphan drugs, the AMNOG considers an added 
medical benefit of an orphan pharmaceutical as proven by means 
of the marketing authorization, unless its turnover at the expense 
of statutory health insurance exceeds €50 million in 12 months. If 
that mark is surpassed, a dossier has to be filed and a full benefit 
assessment takes place, followed by price negotiation.
In England, the assessment of orphan drugs for rare 
conditions is part of the Highly Specialised Technologies 
(HST) program. Following a consultation process in 2017, 
it was recommended that NHS England automatically fund 
drugs for ultra-rare conditions if the ICER of the drug is below 
£100,000 per QALY, a threshold which is substantially higher 
than the one usually applied for drugs (https://www.nice.org.
uk/about/what-we-do/our-programmes/nice-guidance/nice-
technology-appraisal-guidance/consultation-on-changes-to- 
FIGURE 5 | Agreement Between Recommendations and Reimbursement 
Status—metabolic drugs.
FIGURE 3 | Agreement Between Recommendations and Reimbursement 
Status—all drugs.
FIGURE 4 | Agreement Between Recommendations and Reimbursement 
Status—oncologic drugs.
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technology-appraisals-and-highly-specialised-technologies). 
Technologies under the HST program are generally subject to 
a budget impact provision: if their budget impact exceeds £20 
million in any of the first 3 years, negotiations between NHS 
England and the manufacturer may be initiated. The SMC in 
Scotland may consider at a Patient and Clinician Engagement 
(PACE) meeting further aspects of the new active substance for 
treatment of a rare disease, which were not part of the submitted 
manufacturer dossier (https://www.scottishmedicines.org.uk/
how-we-decide).
Given the common framework of the NHS in England 
and Scotland, it is not surprising that recommendations and 
decisions on reimbursement status and between these countries 
achieve the highest agreement. Inversely, the particularity of 
the German reimbursement system, wherein (orphan) drugs 
are automatically reimbursed unless explicitly excluded, 
probably accounts for the lack of agreement regarding the 
recommendations decisions between Germany and the other 
countries. Generally, differences in both reimbursement 
recommendations and status may be due to different agency-
specific evidentiary, risk and value preferences, or stakeholder 
input (Nicod, 2017).
Although some research projects were conducted, there is not 
a similar study evaluating the current situation in various EU 
countries. A study published by Zelei et al. (2016), who reviewed 
scientific evidence on the HTA for orphan drugs decision-
making with a special focus on public payers in CEE countries, 
was identified. The authors revealed that CEE countries are more 
budget-restricted than Western European countries and could be 
more affected by the lack of clinical evidence for orphan drugs, 
which generally gain marketing authorization earlier than non-
orphan drugs.
Szegedi et al. (2018) revealed that the highest expenditure on 
orphan drugs from 2013 to 2014 was observed in Belgium (€245–
280 million), and the lowest, in Bulgaria (€8.3–12.2 million). The 
number of accessible orphan products, also observed in this study, 
suggests an equity gap between Eastern and Western Europe. The 
spending on orphan drugs as a proportion of the gross domestic 
product (GDP) as well as of public pharmaceutical and healthcare 
expenditures was lower in poorer countries, which indicates a 
substantial inequity in terms of patient access to orphan drugs, 
favoring higher-income countries.
Picavet et al. (2012) analyzed access to orphan drugs in 
almost all EU countries (except for Cyprus, Malta, and Portugal) 
based on data from IMS Health (2011). They showed that 
employing an HTA process has an important role in improving 
patients’ access to reimbursed orphan drugs, particularly 
in low-GDP countries. However, nowadays more low-GDP 
countries use a formal HTA process than in 2011; HTA 
process has been shown to play an important role in improving 
patient access to reimbursed orphan drugs, particularly in 
low-GDP countries.
Kamusheva et al. (2018) compared the access of patients with 
rare diseases to biotechnological drugs between several CEE 
countries in 2018, reporting that all these countries implemented 
special legislation for orphan drugs. The share of accessible 
orphan drugs as well as total expenditures varied across 
countries, being the highest in Greece and the lowest in Romania. 
The survey revealed some differences in the legal requirements 
for the pricing and reimbursement of biotechnological orphan 
medicinal products among the countries included in the 
study. All EU countries have developed and implemented 
pharmacoeconomic guidelines with or without some specific 
reimbursement requirements for orphan medicinal products. 
Cost-effectiveness analysis, cost-utility analysis, Markov models, 
meta-analysis, and discount rates for costs and outcomes were 
required only in Bulgaria, Poland, and Hungary. The access to 
orphan medicinal products was similar among the analyzed CEE 
countries, while the countries with the best access were Hungary 
and Greece.
Gammie et al. (2015) analyzed regulations and policies 
used by countries to allow patient access to orphan drugs in 
2015 by performing a systematic review of evidence published 
between 1998 and 2014. They summarized the legislation of 35 
countries from around the world, including 21 EU countries, 
and revealed that different types of special regulations for 
orphan drugs (national orphan drug policies, orphan drug 
designation, marketing authorization, marketing exclusivity, 
and tax credits) were present in most countries. A variation 
in the share of orphan drugs accessible for the patient was 
also observed.
A comparative analysis on the access to orphan drugs 
between the Balkan countries—five EU member states (Bulgaria, 
Croatia, Greece, Romania, and Slovenia) and two EU candidate 
countries (Serbia and Montenegro)—was performed by Pejcic 
et al. (2018). The review revealed significant inequalities 
among these states as well as an inadequate access to orphan 
drugs approved for the EU market; some improvement on the 
access for reimbursement and a better availability of orphan 
drugs for patients are needed.
Our study revealed that the great majority of the 
reimbursement recommendations were positive or conditional 
and about 65% of the considered orphan drugs were reimbursed 
from public funds. The agreement between the type of 
reimbursement recommendations and reimbursement status 
could be influenced by the bias between countries (differences 
in the decision-making process as well as legislation) and by the 
distributions of the reimbursement status. Hence, the presented 
coefficients should be treated as a descriptive statistic rather than 
an inference. In addition, the analysis could not be performed 
when no variation in the analyzed variable existed, like in the case 
of recommendations for metabolic drugs in Germany, while for 
33 metabolic drugs the recommendations were presented for 13 
drugs and all of them were positive. For this reason the agreement 
could not be calculated, as there were no reimbursed drugs with 
negative recommendations or negative recommendations and 
lack of reimbursement.
Our study has some limitations. First of all, we were not 
able to collect relevant data from some European countries, 
as they were not published online and they were also 
unavailable for the collaborating experts and as a result those 
countries were excluded from the analysis. Moreover, our data 
depicts the orphan designations identified until July 2018. 
Due to variations in both orphan drugs designations and 
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reimbursement systems in the analyzed countries, the results 
of our study provide a snapshot of the situation and would need 
to be updated in future works. An ongoing monitoring of the 
reimbursement status of orphan drugs in analyzed countries 
and current trends in reimbursement decision-making for 
orphan drugs would be especially important, but requires 
a structural foundation beyond the abilities of this work. 
Also, although reimbursement status and recommendations 
were examined for 163 identified orphan drugs, it should be 
noted that not all of these orphan drugs are actually on the 
market in the selected countries. Cohen’s kappa coefficient 
of agreement could be calculated only for those countries 
that issued both positive and negative recommendations. In 
addition, the value of this coefficient could be affected by the 
prevalence of levels of the analyzed variables. Only in the cases 
where both recommendation and reimbursement status were 
available, coefficients were analyzed, which results in different 
sets of drugs used to calculate kappa coefficients in different 
countries. The kappa coefficient was close to 0 for Germany; 
this is due to the fact that there were only five negative results 
of the evaluation of additional benefit and all five drugs were 
finally reimbursed, giving 100% disagreement.
Despite those limitations, our study contributes significantly 
to the field of reimbursement of orphan drugs in European 
countries. Providing comprehensive and up-to-date information 
on access to reimbursed orphan drug and reimbursement 
policies, which may facilitate orphan drug management in 
these countries.
CONCLUSIONS
About 65% of identified orphan drugs were reimbursed 
from public funds, and the majority of the reimbursement 
recommendations were found to be positive. Differences between 
countries were observed regarding the number of reimbursement 
recommendations for orphan drugs, the number of particular 
types of recommendations, and the number of reimbursed orphan 
drugs. The agreement between reimbursement recommendations 
and reimbursement status also differed between countries, but 
no patterns could be discerned. This study confirms the existence 
of equity gaps in orphan drug coverage, reflecting variability in 
both willingness and ability to pay.
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